ATE317261T1 - Verwendung von mirtazapin zur behandlung von schlafstörungen - Google Patents

Verwendung von mirtazapin zur behandlung von schlafstörungen

Info

Publication number
ATE317261T1
ATE317261T1 AT01902410T AT01902410T ATE317261T1 AT E317261 T1 ATE317261 T1 AT E317261T1 AT 01902410 T AT01902410 T AT 01902410T AT 01902410 T AT01902410 T AT 01902410T AT E317261 T1 ATE317261 T1 AT E317261T1
Authority
AT
Austria
Prior art keywords
mirtazapine
sleep disorders
treat sleep
treat
disorders
Prior art date
Application number
AT01902410T
Other languages
German (de)
English (en)
Inventor
Gerardus Stephanus Franc Ruigt
Den Berg Frans Van
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE317261T1 publication Critical patent/ATE317261T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01902410T 2000-02-11 2001-02-06 Verwendung von mirtazapin zur behandlung von schlafstörungen ATE317261T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200499 2000-02-11

Publications (1)

Publication Number Publication Date
ATE317261T1 true ATE317261T1 (de) 2006-02-15

Family

ID=8171013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01902410T ATE317261T1 (de) 2000-02-11 2001-02-06 Verwendung von mirtazapin zur behandlung von schlafstörungen

Country Status (25)

Country Link
US (1) US6933293B2 (cg-RX-API-DMAC7.html)
EP (4) EP2283840A1 (cg-RX-API-DMAC7.html)
JP (1) JP5039994B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020069371A (cg-RX-API-DMAC7.html)
CN (2) CN101229170A (cg-RX-API-DMAC7.html)
AR (1) AR027394A1 (cg-RX-API-DMAC7.html)
AT (1) ATE317261T1 (cg-RX-API-DMAC7.html)
AU (1) AU780439B2 (cg-RX-API-DMAC7.html)
BR (1) BR0108261A (cg-RX-API-DMAC7.html)
CA (1) CA2396209C (cg-RX-API-DMAC7.html)
CO (1) CO5271706A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ302368B6 (cg-RX-API-DMAC7.html)
DE (1) DE60117122T2 (cg-RX-API-DMAC7.html)
DK (1) DK1257278T3 (cg-RX-API-DMAC7.html)
ES (1) ES2258071T3 (cg-RX-API-DMAC7.html)
HK (1) HK1049122B (cg-RX-API-DMAC7.html)
HU (1) HUP0204391A3 (cg-RX-API-DMAC7.html)
IL (2) IL150290A0 (cg-RX-API-DMAC7.html)
NO (1) NO328007B1 (cg-RX-API-DMAC7.html)
PE (1) PE20011080A1 (cg-RX-API-DMAC7.html)
PL (1) PL206073B1 (cg-RX-API-DMAC7.html)
RU (1) RU2270680C2 (cg-RX-API-DMAC7.html)
SK (1) SK287396B6 (cg-RX-API-DMAC7.html)
WO (1) WO2001058453A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200205238B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152055A1 (en) * 2003-01-30 2004-08-05 Gliessner Michael J.G. Video based language learning system
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
WO2005051349A2 (en) * 2003-11-25 2005-06-09 Aurobindo Pharma Ltd. Pharmaceutical compositions of mirtazapine
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
AU2005292853C1 (en) * 2004-10-14 2010-08-05 Daikin Industries, Ltd. Atmosphere modifying method and spray agent and spray device used in the same
JP2006137748A (ja) * 2004-10-14 2006-06-01 Daikin Ind Ltd 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置
JP2007284363A (ja) * 2006-04-13 2007-11-01 Daikin Ind Ltd 噴霧剤
WO2008125578A2 (en) 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of mirtazapine
SI3261645T1 (sl) 2015-02-27 2021-08-31 Dechra Limited Stimulacija apetita, uravnavanje izgube mase in zdravljenje anoreksije pri psih in mačkah
CN111053735A (zh) * 2020-02-25 2020-04-24 上海阶平医院管理有限公司 一种治疗失眠的冷敷凝胶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
JPH08502049A (ja) * 1992-10-07 1996-03-05 アクゾ ノーベル ナムローゼ フェンノートシャップ ラセミ体混合物からエナンチオマーを分離する方法
EP0813873B1 (en) * 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ATE289816T1 (de) 1997-11-14 2005-03-15 Akzo Nobel Nv Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen

Also Published As

Publication number Publication date
NO328007B1 (no) 2009-11-09
EP1257278A1 (en) 2002-11-20
US6933293B2 (en) 2005-08-23
NO20023803L (no) 2002-10-09
CZ302368B6 (cs) 2011-04-13
IL150290A0 (en) 2002-12-01
RU2002124141A (ru) 2004-03-10
DE60117122D1 (de) 2006-04-20
PL356721A1 (en) 2004-06-28
CN101229170A (zh) 2008-07-30
DK1257278T3 (da) 2006-06-12
CZ20022330A3 (cs) 2002-11-13
HK1049122A1 (en) 2003-05-02
ES2258071T3 (es) 2006-08-16
HK1049122B (en) 2006-04-21
HUP0204391A3 (en) 2005-03-29
JP5039994B2 (ja) 2012-10-03
AU780439B2 (en) 2005-03-24
JP2003522147A (ja) 2003-07-22
EP1257278B1 (en) 2006-02-08
BR0108261A (pt) 2003-03-05
ZA200205238B (en) 2003-09-29
WO2001058453A1 (en) 2001-08-16
IL150290A (en) 2010-12-30
CO5271706A1 (es) 2003-04-30
EP1656937A1 (en) 2006-05-17
SK287396B6 (sk) 2010-08-09
CN1395487A (zh) 2003-02-05
PL206073B1 (pl) 2010-06-30
AR027394A1 (es) 2003-03-26
DE60117122T2 (de) 2006-07-27
NO20023803D0 (no) 2002-08-09
RU2270680C2 (ru) 2006-02-27
HUP0204391A2 (en) 2003-05-28
EP2283840A1 (en) 2011-02-16
CA2396209A1 (en) 2001-08-16
CA2396209C (en) 2009-09-01
EP1658850A1 (en) 2006-05-24
SK11442002A3 (sk) 2003-02-04
US20030022888A1 (en) 2003-01-30
KR20020069371A (ko) 2002-08-30
PE20011080A1 (es) 2001-10-18
AU3024701A (en) 2001-08-20

Similar Documents

Publication Publication Date Title
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE353218T1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
ATE245032T1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
ATE473753T1 (de) Verwendung von botulinum toxin zur behandlung von post-operative schmerzen
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
ATE327757T1 (de) Verwendung von flibanserin bei der behandung von störungen des sexuellen verlangens
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60015516D1 (de) Verwendung von makroliden zur behandlung von trockenen augen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
EP1491212A4 (en) REMEDY AGAINST SLEEP DISORDERS
ATE339955T1 (de) Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
NO20032156L (no) Behandling av angstforstyrrelser
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE267608T1 (de) Verwendung von fsh zur behandlung von infertilität
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
ATE270545T1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
ATE255892T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung von bulimia nervosa
DE60102471D1 (de) Indolderivate zur verwendung in der behandlung von zns-störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1257278

Country of ref document: EP